CALGARY,
AB, May 23, 2023 /PRNewswire/ - BioAro Inc.
and the Prostate Cancer Centre (PCC) are excited to announce a new
partnership. Together they will change the way metastatic prostate
cancer patients are treated – improving the patients' quality of
life as they navigate their treatment options. BioAro will be
providing complimentary genomic testing services for up to 100
eligible patients referred through specific Urologists of the
Southern Alberta Institute of Urology (SAIU).
This is the first-time genomic testing,
analysis and support for companion diagnostics of this magnitude
has been offered at no cost to AB cancer patients from a local
company.
Genomic testing will assist physicians in predicting the
behaviour or aggressiveness of an individual's cancer and how they
may respond to different treatments. It can also assist with
selection of targeted treatment options that may result in improved
response rates and lower side-effects.
"One in six men in Alberta will be diagnosed with prostate cancer
in their lifetime. This gift will positively impact many of
our patients and their families now, and into the future," says
Jeff Davison, CEO of the PCC.
"Genetic testing will help us advance our search for answers to
this disease that affects so many men and their families in our
province."
The PCC is a charitable organization that provides personalized
care, research and education to men and their families fighting
prostate cancer. The PCC provides continuous support and wrap
around care to those impacted by prostate cancer through
personalized care, consultation, diagnosis, information on
treatment options and access to research – and now genetic testing
can be included in that care.
BioAro Inc, a Calgary-based
Precision Health biotechnology company, is providing equitable
GenOMIC testing & analysis services with detailed genomic
analyses that will help identify genetic biomarkers that can be
used for developing companion diagnostics. BioAro has multiple
laboratories and sample collection centers across Canada, including a local facility in
Calgary, which helps reduce
turnaround time for testing. Samples are tested locally and data is
analyzed and stored within Canada,
helping maintain privacy of Canadian patients.
"We are on a mission to build a community of
individuals, healthcare providers and researchers to transform the
healthcare landscape, drive transformative genetic discovery of
biomarkers for precise and personalized management of our
patients," says Dr. Anmol
Kapoor, CEO of BioAro Inc. "This donation will help so
many individuals (and their families), to hopefully find answers to
their health problems. It would likely help improve the outcomes of
targeted anti-cancer therapy and make GenOMIC testing more
equitable and easier to access."
BioAro Inc. is proud to undertake this initiative with the PCC
to give the gift of equitable GenOMIC testing and information to
prostate cancer families in need.
For more information, please
visit BioAro.com /pcc
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bioaro-inc-to-donate-genomic-testing-free-of-charge-to-100-prostate-cancer-centre-patients-301831761.html
SOURCE BioAro